

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Diagnostics Assessment Programme

Tests in secondary care to identify people at high risk of ovarian cancer

Final stakeholder list

Manufacturer(s) Abbott Laboratories Fujirebio Diagnostics AB International Ovarian Tumor Analysis (IOTA) group Roche Diagnostics Ltd Vermillion, Inc
Professional groups British Association of Gynaecological Pathologists British Gynaecological Cancer Society Institute of Biomedical Science Royal College of Pathologists Royal College of Physicians
Patient/carer groups Ovacome Target Ovarian Cancer The Eve Appeal
Research groups Ovarian Cancer Action
Associated guideline groups None
External Assessment Group Kleijnen Systematic Reviews Ltd
Others British In Vitro Diagnostics Association Department of Health Healthcare Improvement Scotland Medicines & Healthcare Products Regulatory Agency NHS England Welsh Government

Definitions:Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).